Apollomics (APLM) Stock Price, News & Analysis

Company Overview

Apollomics, Inc. (NASDAQ: APLM) is a clinical-stage biopharmaceutical company focused on developing therapies for cancer. The company uses targeted therapeutics and immuno-oncology approaches intended to activate the immune system, improve tumor-cell recognition, and address cancers with limited treatment options.

Apollomics’ pipeline includes investigational antibody-based medicines and other oncology candidates designed for use across a range of solid tumors and hematologic malignancies. Its programs have included therapies directed at tumor-associated targets and immune mechanisms, with development priorities subject to clinical-trial results and regulatory review. The company does not currently have an approved commercial product.

Apollomics was established as an oncology-focused biotechnology company with operations in the United States and connections to the Chinese biopharmaceutical sector. The company has been led by co-founder and Chief Executive Officer Guo-Liang Yu, who has experience in drug discovery and pharmaceutical development.

Key Stats

• Today's Range: $23.00 to $23.27
• 50-Day Range: $17.00 to $28.01
• 52-Week Range: $10.01 to $42.12
• Volume: 1,164 shs
• Average Volume: 10,334 shs
• Market Capitalization: $68.85 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Apollomics Stock Analysis - MarketRank™

Apollomics scored higher than 33% of companies evaluated by MarketBeat, and ranked 720th out of 888 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Apollomics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Apollomics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: N/A
• Proj. Earnings Growth: N/A

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.19% of the float of Apollomics has been sold short.

Short Interest Ratio / Days to Cover

Apollomics has a short interest ratio ("days to cover") of 0.46, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Apollomics has recently decreased by 23.90%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Apollomics does not currently pay a dividend.

Dividend Growth

Apollomics does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

MarketBeat Follows

1 people have added Apollomics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 3.8 / 5
• Insider Trading: Acquiring Shares

Cluster Insider Buying

3 insiders have purchased shares of Apollomics in the last three months. Multiple insiders buying is a strong bullish signal.

Net Insider Buying

Over the last three months, insiders have purchased a net $8,250,510.00 in company stock, which represents 11.9827% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Apollomics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $8,250,510.00 in company stock and sold $0.00 in company stock.

Percentage Held by Institutions

19.13% of the stock of Apollomics is held by institutions.

Company Calendar

• Today: 10/03/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:APLM
• CIK: 1944885
• Web: www.apollomicsinc.com
• Phone: 886-2-7713-7952
• Fax: 650-288-1674
• Employees: 15
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $8.50 million
• Price / Sales: 8.10
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($2.89) per share
• Price / Book: -8.19

Miscellaneous

• Outstanding Shares: 2,910,000
• Free Float: N/A
• Market Cap: $68.85 million
• Optionable: Not Optionable
• Beta: 1.54